[A17-53] Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25
Last updated 17.11.2017
Project no.:
A17-53
Commission:
Commission awarded on 09.10.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Indication:
Secondary hyperparathyroidism
Result of dossier assessment:
Study 20120360: neither advantage nor disadvantage proven for etelcalcetide in comparison with cinacalcet
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-25 | Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-11-17 A G-BA decision was published.